ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company that specializes in creating orally administered new medicines that inhibit chemo-attractant receptors – the engines of cell migration in disease. The company focuses exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. By altering the cellular microenvironment in diseases of inflammation, autoimmunity, and cancer, the company intends to generate better treatment outcomes. For more information, visit the company’s website at www.chemocentryx.com.